Pharmaceuticals France

France PTSD Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France PTSD Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Population, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $41.2 Mn Placeholder estimate
Estimate 2025 $43.2 Mn 2.6% of the global market
Projected 2034 $66.5 Mn 53.8% Adds $23.3 Mn over 9 forecast years
CAGR 2025–2034 4.9% Faster than 23% of 180 Pharmaceuticals markets here
Key players 5
  • France is 2.57% of the global market.
  • In Europe, the largest is Germany at $67.3 Mn.
  • Fastest growing: Russia at 5.9% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$23.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
PTSD Treatment Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $41.2 Mn — —
2025 (base) $43.2 Mn +$2.0 Mn —
2026 (forecast) $45.4 Mn +$2.1 Mn +4.9%
2027 (forecast) $47.6 Mn +$2.2 Mn +10%
2028 (forecast) $49.9 Mn +$2.3 Mn +15.4%
2029 (forecast) $52.4 Mn +$2.4 Mn +21.1%
2030 (forecast) $54.9 Mn +$2.6 Mn +27%
2031 (forecast) $57.6 Mn +$2.7 Mn +33.2%
2032 (forecast) $60.4 Mn +$2.8 Mn +39.8%
2033 (forecast) $63.4 Mn +$3.0 Mn +46.6%
2034 (forecast) $66.5 Mn +$3.1 Mn +53.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France PTSD Treatment Market Analysis at a glance
Market size, 2025$43.2 Mn placeholder estimate
Forecast, 2034$66.5 Mn placeholder estimate
Growth (CAGR), 2025–20344.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledPost-Traumatic Stress Disorder Treatment
SegmentsTreatment, population and end user (see all)
Key playersPfizer Inc., Viatris, Lykos Therapeutics, Otsuka Pharmaceutical Co., Ltd., Tonix Pharmaceuticals (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
Active clinical trials29 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France PTSD Treatment Market Analysis Executive Summary

PTSD treatment helps people recover from trauma using therapies, medicines and new approaches such as MDMA-assisted therapy.

Key segments of the PTSD Treatment market include treatment (Psychotherapy, SSRIs and SNRIs and Psychedelic-Assisted Therapy) and population (Veterans and Military and Civilians).

Bar chart: France PTSD Treatment market size, 2024–2034, placeholder estimates. $41.2 Mn in 2024, $43.2 Mn in 2025 and $66.5 Mn in 2034, 4.9% CAGR.
France PTSD Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France PTSD Treatment Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the PTSD Treatment market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the PTSD Treatment market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the PTSD Treatment market.

Competitive Landscape for PTSD Treatment Market in France

The PTSD Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for PTSD Treatment Market in France

PTSD Treatment in France: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2] ClinicalTrials.gov lists 29 studies on PTSD Treatment that are recruiting, active or about to start in France.⁠[3] Suicide rate: 16.5 per 100,000 people in 2023, the latest WHO figure for France.⁠[4]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for PTSD Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in PTSD Treatment right now, from free public sources.

Clinical trials

29 active trials in France

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Transcend Therapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

PTSD Treatment in context

France compared

  • Suicide rate: 16.5 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 2nd highest of the 6 countries we cover in Europe.[1]
  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[2]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the PTSD Treatment market in France?
Placeholder estimate: about $43.2 Mn in 2025, rising to about $66.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the PTSD Treatment market in France growing?
Placeholder estimate: about 4.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the PTSD Treatment market report cover?
The report splits the market by treatment (Psychotherapy, SSRIs and SNRIs, Psychedelic-Assisted Therapy, Digital Therapy), population (Veterans and Military, Civilians) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the PTSD Treatment market?
Key players include Pfizer Inc., Viatris, Lykos Therapeutics, Otsuka Pharmaceutical Co., Ltd. and Tonix Pharmaceuticals.
What is driving the PTSD Treatment market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the PTSD Treatment market. Governments and employers are investing more in mental health care.
Who regulates PTSD Treatment in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How many clinical trials on PTSD Treatment are running in France?
29 studies are recruiting, active or about to start in France, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
What does WHO report for France?
Suicide rate: 16.5 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in France are 65 or older?
22.5% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on mental health

See the topic